drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Afucosylated human IgG1 monoclonal antibody (AMG 451/KHK4083) targeting OX40 (CD134); blocks OX40–OX40L costimulatory signaling and promotes ADCC-mediated depletion of OX40+ activated/effector-memory T cells to reduce T cell–driven airway inflammation and type 2 cytokines (IL-4, IL-5, IL-13). Administered subcutaneously.
nci_thesaurus_concept_id
C184936
drug_mesh_term
Antibodies, Monoclonal
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Afucosylated human IgG1 monoclonal antibody targeting OX40 (CD134) that blocks OX40–OX40L costimulatory signaling and enhances ADCC to deplete OX40+ activated/effector-memory T cells, reducing type 2 cytokines (IL-4, IL-5, IL-13) and T cell–driven inflammation.
drug_name
Rocatinlimab
nct_id_drug_ref
NCT06376045